Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VIPERFAV
- Development stage
- Unknown
- Lead developer
- MicroPharm
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
VIPERFAV is a polyvalent equine-derived antivenom composed of F(ab')2 antibody fragments. It is specifically designed to neutralize the venom of the three most common European vipers: *Vipera aspis*, *Vipera berus*, and *Vipera ammodytes*. The drug is produced by pepsin digestion of whole IgG from horses immunized with these specific viper venoms, a process that removes the Fc portion of the antibody to reduce the risk of Fc-mediated adverse reactions while maintaining high neutralizing potency. VIPERFAV is indicated for the treatment of severe snake envenoming caused by these species and is currently marketed by MicroPharm, having historically been developed and manufactured by Sanofi Pasteur. It holds a Marketing Authorisation from the French National Agency for the Safety of Medicines and Health Products (ANSM).
- Brand names
- VIPERFAV
- Other names
- Equine F(ab')2 antivenomEuropean viper antivenomAntivipérinviper venom antiserum (equine)
02
Targets
Vipera ammodytes venom toxin antigenVipera berus venom toxin antigensVipera aspis venom toxins
Beyond the preview
Go deeper on VIPERFAV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VIPERFAV.